The global Sever s Disease Treatment Market size is calculated at USD 1.34 billion in 2024 and is expected to be worth around USD 1.87 billion by 2031,.
US Subsidiary of IBSA to Commercialize Generic PortfolioPARSIPPANY, N.J. (BUSINESS WIRE) Yaral Pharma Inc., the US generics subsidiary of IBSA, a long-standing, multinational pharmaceutical company headquartered in Lugano, Switzerland, launched today with the mission of providing access to high quality, affordable.